Therapeutic potential and pharmacological activities of β‐eudesmol. (7th February 2021)

• Record Type: Journal Article
• Authors: Acharya, Bishwanath; Chaijaroenkul, Wanna; Na‐Bangchang, Kesara
• Is Part Of: Chemical biology & drug design. Volume 97:Number 4(2021)
• Page Start: 984
• Page End: 996
• Publication Date: 2021-02-07
• Subjects: Atractylodes lancea -- bioactive sesquiterpenes -- β‐eudesmol; Drugs -- Design -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; 615.19005
• DOI: 10.1111/cbdd.13823
• Languages: English
• ISSNs: 1747-0277

Abstract

Abstract: Herbal medicines are attracting the attention of researchers worldwide. β‐Eudesmol is one of the most studied and major bioactive sesquiterpenes, mainly extracted from Atractylodes lancea (Thunb) DC. rhizomes. It has potential anti‐tumor and anti‐angiogenic activities and is an inhibitor of tumor growth by inhibiting angiogenesis by suppressing CREB activation of the growth factor signaling pathway. It also stimulates neurite outgrowth in rat pheochromocytoma cells with activation of mitogen‐activated protein kinases. It may be a promising lead compound for enhancing neural function, and it may help to explain the underlying mechanisms of neural differentiation. In this review, we summarized the currently available clinical and preclinical studies describing the therapeutic applications of β‐eudesmol. Abstract : β‐Eudesmol is a major bioactive compound extracted from Atractylodes lancea rhizomes. It has potential anti‐tumor and anti‐angiogenic activities by suppressing CREB activation and stimulating mitogen‐activated protein kinases. It may be a promising lead compound for enhancing neural function, and it may help to explain the underlying mechanisms of neural differentiation.